NCT06941870View on ClinicalTrials.gov

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

March 16, 2027

Study Completion Date

June 15, 2027

Conditions

Factor VIII Deficiency

Interventions

DRUG

Efanesoctocog alfa

Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous